Lord, Abbett & Co
IMNM icon

Lord, Abbett & Co’s Immunome IMNM Stock Holding History

Lord, Abbett & Co’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-450,280
Closed -$6.58M – 552
2024
Q3 		$6.58M Buy
450,280
+17,566
+4% +$250K 0.02% 447
2024
Q2 		$5.24M Sell
432,714
-12,721
-3% -$199K 0.02% 461
2024
Q1 		$11M Buy
+445,435
New +$9.04M 0.04% 389

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's IMNM Position: Q4 2024 in Review

Lord, Abbett & Co sold out of Immunome (IMNM) in Q4 2024, closing a stake of 450,280 shares — an estimated $6.58M sold.

Lord, Abbett & Co first reported a position in IMNM in Q1 2024 and held it in 3 quarters. The position peaked at $11M in Q1 2024. 120 funds tracked by Wall St. Rank hold IMNM as of Q4 2024.

  • Lord, Abbett & Co reported no remaining Immunome position as of Q4 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 450,280 Immunome shares in Q4 2024, an estimated $6.58M.
  • Lord, Abbett & Co first reported a position in Immunome in Q1 2024 and held it in 3 quarters.
  • Lord, Abbett & Co's Immunome position peaked at $11M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Immunome as of Q4 2024.

Based on Lord, Abbett & Co's 13F filing for Q4 2024, filed 14 Feb 2025.